Early clinical studies show substantial weight loss outcomes, often exceeding results seen with single-receptor agonists
Sam Hawley: And you spoke to one doctor, Dr Michael Fox, who's in Tasmania
Among type 2 diabetic patients with or without AD who were treated with GLP-1RAs, no differences were seen in the risks for mortality, new-onset MACE, MI, heart failure, or stroke
Research indicates that HGF activation provides neuroprotective effects in cerebral ischemia, spinal cord injuries, and traumatic brain damage by promoting neuronal survival, stimulating angiogenesis, and reducing apoptosis
Overcoming this barrier is not merely a formulation problem